Themes and variations in ER/SR calcium release channels: Structure and function

Physiology

Volumn 27, Issue 6, 2012, Pages 331-342

  Stathopulos, Peter B ^a   Seo, Min Duk ^b   Enomoto, Masahiro ^a   Amador, Fernando J ^a   Ishiyama, Noboru ^a   Ikura, Mitsuhiko ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Ajou University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CHANNEL; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; RYANODINE RECEPTOR;

ANIMAL; CHEMISTRY; ENDOPLASMIC RETICULUM; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SARCOPLASMIC RETICULUM;

ANIMALS; CALCIUM; CALCIUM CHANNELS; ENDOPLASMIC RETICULUM; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM;

EID: 84870791465     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00013.2012     Document Type: Review

References (141)

1. Amador FJ, Liu S, Ishiyama N, Plevin MJ, Wilson A, MacLennan DH, Ikura M. Crystal structure of type I ryanodine receptor amino-terminal beta-trefoil domain reveals a disease-associated mutation "hot spot" loop. Proc Natl Acad Sci USA 106: 11040-11044, 2009.
2. Avila G, Dirksen RT. Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor. J Gen Physiol 118: 277-290, 2001.
3. Baylis H. Inositol 1,4,5-trisphosphate receptors are strongly expressed in the nervous system, pharynx, intestine, gonad and excretory cell of Caenorhabditis elegans and are encoded by a single gene (itr-1). J Mol Biol 294: 467-476, 1999.
4. Berridge MJ. Cell Signalling Biology. London: Portland Press, 2009.
5. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 4: 517-529, 2003.
6. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 1: 11-21, 2000.
7. Bezprozvanny I, Watras J, Ehrlich BE. Bell-shaped calciumresponse curves of Ins(1,4,5)P3-and calcium-gated channels from endoplasmic reticulum of cerebellum. Nature 351: 751-754, 1991.
8. Bhuiyan ZA, van den Berg MP, van Tintelen JP, Bink-Boelkens MT, Wiesfeld AC, Alders M, Postma AV, van Langen I, Mannens MM, Wilde AA. Expanding spectrum of human RYR2- related disease: new electrocardiographic, structural, and genetic features. Circulation 116: 1569-1576, 2007.
9. Blondel O, Takeda J, Janssen H, Seino S, Bell GI. Sequence and functional characterization of a third inositol trisphosphate receptor subtype, IP3R-3, expressed in pancreatic islets, kidney, gastrointestinal tract, and other tissues. J Biol Chem 268: 11356-11363, 1993.
10. Bosanac I, Alattia JR, Mal TK, Chan J, Talarico S, Tong FK, Tong KI, Yoshikawa F, Furuichi T, Iwai M, Michikawa T, Mikoshiba K, Ikura M. Structure of the inositol 1,4,5-trisphosphate receptor binding core in complex with its ligand. Nature 420: 696-700, 2002.
11. Bosanac I, Yamazaki H, Matsu-Ura T, Michikawa T, Mikoshiba K, Ikura M. Crystal structure of the ligand binding suppressor domain of type 1 inositol 1,4,5-trisphosphate receptor. Mol Cell 17: 193-203, 2005.
12. Bouchama A, Knochel JP. Heat stroke. N Engl J Med 346: 1978-1988, 2002.
13. Brandom BW, Larach MG, Chen MS, Young MC. Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesth Analg 112: 1115-1123, 2011.
14. Bush KT, Stuart RO, Li SH, Moura LA, Sharp AH, Ross CA, Nigam SK. Epithelial inositol 1,4,5-trisphosphate receptors. Multiplicity of localization, solubility, and isoforms. J Biol Chem 269: 23694-23699, 1994.
15. 2+ signaling "toolkit" at the origin of metazoa. Mol Biol Evol 25: 1357-1361, 2008.
16. 2+ signaling machinery in early animal and fungal evolution. Mol Biol Evol 29: 91-100, 2011.
17. 2+ mobilization pathways at the vacuolar membrane of Candida albicans. J Biol Chem 270: 7272-7280, 1995.
18. Capacchione JF, Muldoon SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg 109: 1065-1069, 2009.
19. Castresana J. Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis. Mol Biol Evol 17: 540-552, 2000.
20. Chan J, Whitten AE, Jeffries CM, Bosanac I, Mal TK, Ito J, Porumb H, Michikawa T, Mikoshiba K, Trewhella J, Ikura M. Ligand-induced conformational changes via flexible linkers in the amino-terminal region of the inositol 1,4,5-trisphosphate receptor. J Mol Biol 373: 1269-1280, 2007.
21. Chan J, Yamazaki H, Ishiyama N, Seo MD, Mal TK, Michikawa T, Mikoshiba K, Ikura M. Structural studies of inositol 1,4,5-trisphosphate receptor: coupling ligand binding to channel gating. J Biol Chem 285: 36092-36099, 2010.
22. Cornelius G, Gebauer G, Techel D. Inositol trisphosphate induces calcium release from Neurospora crassa vacuoles. Biochem Biophys Res Commun 162: 852-856, 1989.
23. Corrado D, Basso C, Thiene G. Arrhythmogenic right ventricular cardiomyopathy: diagnosis, prognosis, and treatment. Heart 83: 588-595, 2000.
24. da Fonseca PC, Morris SA, Nerou EP, Taylor CW, Morris EP. Domain organization of the type 1 inositol 1,4,5-trisphosphate receptor as revealed by single-particle analysis. Proc Natl Acad Sci USA 100: 3936-3941, 2003.
25. De Rosa G, Delogu AB, Piastra M, Chiaretti A, Bloise R, Priori SG. Catecholaminergic polymorphic ventricular tachycardia: successful emergency treatment with intravenous propranolol. Pediatr Emerg Care 20: 175-177, 2004.
26. De Smedt F, Verjans B, Mailleux P, Erneux C. Cloning and expression of human brain type I inositol 1,4,5-trisphosphate 5-phosphatase. High levels of mRNA in cerebellar Purkinje cells. FEBS Lett 347: 69-72, 1994.
27. De Smedt H, Missiaen L, Parys JB, Bootman MD, Mertens L, Van Den Bosch L, Casteels R. Determination of relative amounts of inositol trisphosphate receptor mRNA isoforms by ratio polymerase chain reaction. J Biol Chem 269: 21691-21698, 1994.
28. De Smedt H, Missiaen L, Parys JB, Henning RH, Sienaert I, Vanlingen S, Gijsens A, Himpens B, Casteels R. Isoform diversity of the inositol trisphosphate receptor in cell types of mouse origin. Biochem J 322: 575-583, 1997.
29. Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth 34: 395-396, 1962.
30. 2+ release channels? Trends Cardiovasc Med 12: 189-197, 2002.
31. Durham WJ, Aracena-Parks P, Long C, Rossi AE, Goonasekera SA, Boncompagni S, Galvan DL, Gilman CP, Baker MR, Shirokova N, Protasi F, Dirksen R, Hamilton SL. RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice. Cell 133: 53-65, 2008.
32. Eldar M, Pras E, Lahat H. A missense mutation in the CASQ2 gene is associated with autosomal- recessive catecholamine-induced polymorphic ventricular tachycardia. Trends Cardiovasc Med 13: 148-151, 2003.
33. Endo M, Tanaka M, Ogawa Y. Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. Nature 228: 34-36, 1970.
34. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol Cell Physiol 245: C1-C14, 1983.
35. Finch E, Turner T, Goldin S. Calcium as a coagonist of inositol 1,4,5-trisphosphate-induced calcium release. Science 252: 443-446, 1991.
36. 2+ release channels. Physiol Rev 87: 593-658, 2007.
37. 2+ release channels are differentially expressed in rabbit brain. J Neurosci 14: 4794-4805, 1994.
38. Furuichi T, Yoshikawa S, Miyawaki A, Wada K, Maeda N, Mikoshiba K. Primary structure and functional expression of the inositol 1,4,5-trisphosphate-binding protein P400. Nature 342: 32-38, 1989.
39. 2+ channel that is regulated by TGF-beta. Science 257: 91-94, 1992.
40. Giannini G, Conti A, Mammarella S, Scrobogna M, Sorrentino V. The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues. J Cell Biol 128: 893-904, 1995.
41. Gyorke I, Hester N, Jones LR, Gyorke S. The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium. Biophys J 86: 2121-2128, 2004.
42. Hakamata Y, Nakai J, Takeshima H, Imoto K. Primary structure and distribution of a novel ryanodine receptor/calcium release channel from rabbit brain. FEBS Lett 312: 229-235, 1992.
43. Hamada K, Miyata T, Mayanagi K, Hirota J, Mikoshiba K. Two-state conformational changes in inositol 1,4,5-trisphosphate receptor regulated by calcium. J Biol Chem 277: 21115-21118, 2002.
44. Hamada K, Terauchi A, Mikoshiba K. Three-dimensional rearrangements within inositol 1,4,5- trisphosphate receptor by calcium. J Biol Chem 278: 52881-52889, 2003.
45. Haugaa KH, Leren IS, Berge KE, Bathen J, Loennechen JP, Anfinsen OG, Fruh A, Edvardsen T, Kongsgard E, Leren TP, Amlie JP. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation- positive family members diagnosed by cascade genetic screening. Europace 12: 417-423, 2010.
46. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 119: 2426-2434, 2009.
47. Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet 338: 1491-1492, 1991.
48. 2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 4: 128-135, 2011.
49. 2+ channels in planar bilayers. Proc Natl Acad Sci USA 85: 441-445, 1988.
50. 2+ -permeable pore of the calcium release channel. J Biol Chem 262: 16636-16643, 1987.
51. Iwai M, Michikawa T, Bosanac I, Ikura M, Mikoshiba K. Molecular basis of the isoform-specific ligand-binding affinity of inositol 1,4,5-trisphosphate receptors. J Biol Chem 282: 12755-12764, 2007.
52. Iwai M, Tateishi Y, Hattori M, Mizutani A, Nakamura T, Futatsugi A, Inoue T, Furuichi T, Michikawa T, Mikoshiba K. Molecular cloning of mouse type 2 and type 3 inositol 1,4,5-trisphosphate receptors and identification of a novel type 2 receptor splice variant. J Biol Chem 280: 10305-10317, 2005.
53. Jiang QX, Thrower EC, Chester DW, Ehrlich BE, Sigworth FJ. Three-dimensional structure of the type 1 inositol 1,4,5-trisphosphate receptor at 24 A resolution. EMBO J 21: 3575-3581, 2002.
54. Jungbluth H. Central core disease. Orphanet J Rare Dis 2: 25, 2007.
55. Jungbluth H. Multi-minicore Disease. Orphanet J Rare Dis 2: 31, 2007.
56. Jungbluth H, Muller CR, Halliger-Keller B, Brockington M, Brown SC, Feng L, Chattopadhyay A, Mercuri E, Manzur AY, Ferreiro A, Laing NG, Davis MR, Roper HP, Dubowitz V, Bydder G, Sewry CA, Muntoni F. Autosomal recessive inheritance of RYR1 mutations in a congenital myopathy with cores. Neurology 59: 284-287, 2002.
57. Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 23: 4-17, 2000.
58. Katoh K, Toh H. Parallelization of the MAFFT multiple sequence alignment program. Bioinformatics 26: 1899-1900, 2010.
59. Kobayashi S, Yano M, Suetomi T, Ono M, Tateishi H, Mochizuki M, Xu X, Uchinoumi H, Okuda S, Yamamoto T, Koseki N, Kyushiki H, Ikemoto N, Matsuzaki M. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol 53: 1993-2005, 2009.
60. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene: a review of its pharmacology, therapeutic use and new developments. Anaesthesia 59: 364-373, 2004.
61. Ladenburger EM, Korn I, Kasielke N, Wassmer T, Plattner H. An Ins(1,4,5)P3 receptor in Paramecium is associated with the osmoregulatory system. J Cell Sci 119: 3705-3717, 2006.
62. 2+ -release channel isoform in mammalian brain. Biochem J 288: 553-564, 1992.
63. Laitinen PJ, Swan H, Kontula K. Molecular genetics of exercise-induced polymorphic ventricular tachycardia: identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms. Eur J Hum Genet 11: 888-891, 2003.
64. Lanner JT. Ryanodine receptor physiology and its role in disease. Adv Exp Med Biol 740: 217-234, 2012.
65. Lanner JT, Georgiou DK, Joshi AD, Hamilton SL. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol 2: a003996, 2010.
66. Lin CC, Baek K, Lu Z. Apo and InsP(3)-bound crystal structures of the ligand-binding domain of an InsP(3) receptor. Nat Struct Mol Biol 18: 1172-1174, 2011.
67. Liu N, Ruan Y, Denegri M, Bachetti T, Li Y, Colombi B, Napolitano C, Coetzee WA, Priori SG. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C /) mice with catecholaminergic polymorphic ventricular tachycardia. J Mol Cell Cardiol 50: 214-222, 2011.
68. Lobo PA, Kimlicka L, Tung CC, Van Petegem F. The deletion of exon 3 in the cardiac ryanodine receptor is rescued by beta strand switching. Structure 19: 790-798, 2011.
69. Lobo PA, Van Petegem F. Crystal structures of the N-terminal domains of cardiac and skeletal muscle ryanodine receptors: insights into disease mutations. Structure 17: 1505-1514, 2009.
70. Ludtke SJ, Serysheva II, Hamilton SL, Chiu W. The pore structure of the closed RyR1 channel. Structure 13: 1203-1211, 2005.
71. Ludtke SJ, Tran TP, Ngo QT, Moiseenkova-Bell VY, Chiu W, Serysheva II. Flexible architecture of IP3R1 by Cryo-EM. Structure 19: 1192-1199, 2011.
72. Mackrill JJ. Ryanodine receptor calcium release channels: an evolutionary perspective. Adv Exp Med Biol 740: 159-182, 2012.
73. Maranto AR. Primary structure, ligand binding, and localization of the human type 3 inositol 1,4,5-trisphosphate receptor expressed in intestinal epithelium. J Biol Chem 269: 1222-1230, 1994.
74. Marks AR, Priori S, Memmi M, Kontula K, Laitinen PJ. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. J Cell Physiol 190: 1-6, 2002.
75. Marks AR, Tempst P, Hwang KS, Taubman MB, Inui M, Chadwick C, Fleischer S, Nadal-Ginard B. Molecular cloning and characterization of the ryanodine receptor/junctional channel complex cDNA from skeletal muscle sarcoplasmic reticulum. Proc Natl Acad Sci USA 86: 8683-8687, 1989.
76. Maryon EB, Coronado R, Anderson P. Unc-68 encodes a ryanodine receptor involved in regulating C. elegans body-wall muscle contraction. J Cell Biol 134: 885-893, 1996.
77. 2+ in a protist, Euglena gracilis. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 118: 279-283, 1997.
78. Matsu-ura T, Michikawa T, Inoue T, Miyawaki A, Yoshida M, Mikoshiba K. Cytosolic inositol 1,4,5- trisphosphate dynamics during intracellular calcium oscillations in living cells. J Cell Biol 173: 755-765, 2006.
79. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, Hofman N, Bikker H, van Tintelen JP, Mannens MM, Wilde AA, Ackerman MJ. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol 54: 2065-2074, 2009.
80. 2+ release channel of sarcoplasmic reticulum. J Biol Chem 261: 6300-6306, 1986.
81. Mignery GA, Südhof TC, Takei K, De Camilli P. Putative receptor for inositol 1,4,5-trisphosphate similar to ryanodine receptor. Nature 342: 192-195, 1989.
82. 2+ -ATPase: design of a perfect chemi-osmotic pump. Q Rev Biophys 43: 501-566, 2010.
83. Muthappan P, Calkins H. Arrhythmogenic right ventricular dysplasia. Prog Cardiovasc Dis 51: 31-43, 2008.
84. Nakagawa T, Shiota C, Okano H, Mikoshiba K. Differential localization of alternative spliced transcripts encoding inositol 1,4,5-trisphosphate receptors in mouse cerebellum and hippocampus: in situ hybridization study. J Neurochem 57: 1807-1810, 1991.
85. Nakai J, Imagawa T, Hakamat Y, Shigekawa M, Takeshima H, Numa S. Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel. FEBS Lett 271: 169-177, 1990.
86. Nakanishi S, Kuwajima G, Mikoshiba K. Immunohistochemical localization of ryanodine receptors in mouse central nervous system. Neurosci Res 15: 130-142, 1992.
87. Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 4: 675-678, 2007.
88. 2+ regulating proteins. Curr Mol Med 2: 347-369, 2002.
89. Newton CL, Mignery GA, Südhof TC. Co-expression in vertebrate tissues and cell lines of multiple inositol 1,4,5-trisphosphate (InsP3) receptors with distinct affinities for InsP3. J Biol Chem 269: 28613-28619, 1994.
90. 2+ release channels are expressed in vascular smooth muscle. Biochem Biophys Res Commun 215: 814-821, 1995.
91. 2+ release channel (ryanodine receptor) of rabbit cardiac muscle sarcoplasmic reticulum. J Biol Chem 265: 13472-13483, 1990.
92. Ottini L, Marziali G, Conti A, Charlesworth A, Sorrentino V. Alpha and beta isoforms of ryanodine receptor from chicken skeletal muscle are the homologues of mammalian RyR1 and RyR3. Biochem J 315: 207-216, 1996.
93. 3H]azidodantrolene: synthesis and use in identification of a putative skeletal muscle dantrolene binding site in sarcoplasmic reticulum. J Med Chem 42: 1872-1880, 1999.
94. Pamukcoglu T. Sudden death due to malignant hyperthermia. Am J Forensic Med Pathol 9: 161-162, 1988.
95. Parness J, Palnitkar SS. Identification of dantrolene binding sites in porcine skeletal muscle sarcoplasmic reticulum. J Biol Chem 270: 18465-18472, 1995.
96. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103: 196-200, 2001.
97. Prole DL, Taylor CW. Identification of intracellular and plasma membrane calcium channel homologues in pathogenic parasites. PLos One 6: e26218, 2011.
98. Quane KA, Healy JM, Keating KE, Manning BM, Couch FJ, Palmucci LM, Doriguzzi C, Fagerlund TH, Berg K, Ording H, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 5: 51-55, 1993.
99. Radermacher M, Rao V, Grassucci R, Frank J, Timerman AP, Fleischer S, Wagenknecht T. Cryoelectron microscopy and three-dimensional reconstruction of the calcium release channel/ ryanodine receptor from skeletal muscle. J Cell Biol 127: 411-423, 1994.
100. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 27: 977-989, 2006.
101. Robinson RL, Brooks C, Brown SL, Ellis FR, Halsall PJ, Quinnell RJ, Shaw MA, Hopkins PM. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutat 20: 88-97, 2002.
102. Roderick HL, Berridge MJ, Bootman MD. Calcium-induced calcium release. Curr Biol 13: R425, 2003.
103. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis 2: 21, 2007.
104. Ross CA, Danoff SK, Schell MJ, Snyder SH, Ullrich A. Three additional inositol 1,4,5-trisphosphate receptors: molecular cloning and differential localization in brain and peripheral tissues. Proc Natl Acad Sci USA 89: 4265-4269, 1992.
105. Rossi AM, Riley AM, Tovey SC, Rahman T, Dellis O, Taylor EJ, Veresov VG, Potter BV, Taylor CW. Synthetic partial agonists reveal key steps in IP3 receptor activation. Nat Chem Biol 5: 631-639, 2009.
106. Ryan JF, Tedeschi LG. Sudden unexplained death in a patient with a family history of malignant hyperthermia. J Clin Anesth 9: 66-68, 1997.
107. Sakube Y, Ando H, Kagawa H. Cloning and mapping of a ryanodine receptor homolog gene of Caenorhabditis elegans. Ann NY Acad Sci 707: 540-545, 1993.
108. Samso M, Feng W, Pessah IN, Allen PD. Coordinated movement of cytoplasmic and transmembrane domains of RyR1 upon gating. PLoS Biol 7: e85, 2009.
109. Samso M, Wagenknecht T, Allen PD. Internal structure and visualization of transmembrane domains of the RyR1 calcium release channel by cryo-EM. Nat Struct Mol Biol 12: 539-544, 2005.
110. Sato C, Hamada K, Ogura T, Miyazawa A, Iwasaki K, Hiroaki Y, Tani K, Terauchi A, Fujiyoshi Y, Mikoshiba K. Inositol 1,4,5-trisphosphate receptor contains multiple cavities and L-shaped ligand-binding domains. J Mol Biol 336: 155-164, 2004.
111. Seo MD, Velamakanni S, Ishiyama N, Stathopulos PB, Rossi AM, Khan SA, Dale P, Li C, Ames JB, Ikura M, Taylor CW. Structural and functional conservation of key domains in InsP3 and ryanodine receptors. Nature 483: 108-112, 2012.
112. Serysheva II, Bare DJ, Ludtke SJ, Kettlun CS, Chiu W, Mignery GA. Structure of the type 1 inositol 1,4,5-trisphosphate receptor revealed by electron cryomicroscopy. J Biol Chem 278: 21319-21322, 2003.
113. Serysheva II, Orlova EV, Chiu W, Sherman MB, Hamilton SL, van Heel M. Electron cryomicroscopy and angular reconstitution used to visualize the skeletal muscle calcium release channel. Nat Struct Biol 2: 18-24, 1995.
114. Sewry CA, Muller C, Davis M, Dwyer JS, Dove J, Evans G, Schroder R, Furst D, Helliwell T, Laing N, Quinlivan RC. The spectrum of pathology in central core disease. Neuromuscul Disord 12: 930-938, 2002.
115. 2+ release channels in rat brain. J Neurosci 13: 3051-3063, 1993.
116. Shibao K, Hirata K, Robert ME, Nathanson MH. Loss of Inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis. Gastroenterology 125: 1175-1187, 2003.
117. Shinohara T, Michikawa T, Enomoto M, Goto J, Iwai M, Matsuura T, Yamazaki H, Miyamoto A, Suzuki A, Mikoshiba K. Mechanistic basis of bell- shaped dependence of inositol 1,4,5-trisphosphate receptor gating on cytosolic calcium. Proc Natl Acad Sci USA 108: 15486-15491, 2011.
118. Südhof TC, Newton CL, Archer BT, Ushkaryov YA, Mignery GA. Structure of a novel InsP3 receptor. EMBO J 10: 3199-3206, 1991.
119. 2+ release leading to catecholaminergic polymorphic ventricular tachycardia. Circulation 124: 682-694, 2011.
120. Sugawara H, Kurosaki M, Takata M, Kurosaki T. Genetic evidence for involvement of type 1, type 2 and type 3 inositol 1,4,5-trisphosphate receptors in signal transduction through the B-cell antigen receptor. EMBO J 16: 3078-3088, 1997.
121. Tae H, Casarotto MG, Dulhunty AF. Ubiquitous SPRY domains and their role in the skeletal type ryanodine receptor. Eur Biophys J 39: 51-59, 2009.
122. Takeshima H, Nishimura S, Matsumoto T, Ishida H. Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. Nature 339: 439-445, 1989.
123. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28: 2731-2739, 2011.
124. Tamura T, Hashimoto M, Aruga J, Konishi Y, Nakagawa M, Ohbayashi T, Shimada M, Mikoshiba K. Promoter structure and gene expression of the mouse inositol 1,4,5-trisphosphate receptor type 3 gene. Gene 275: 169-176, 2001.
125. 2+ leak in failing hearts. Cardiovasc Res 81: 536-545, 2009.
126. Taylor CW, Genazzani AA, Morris SA. Expression of inositol trisphosphate receptors. Cell Calcium 26: 237-251, 1999.
127. 3 Receptors. Subcell Biochem 59: 1-34, 2012.
128. Terentyev D, Kubalova Z, Valle G, Nori A, Vedamoorthyrao S, Terentyeva R, ViatchenkoKarpinski S, Bers DM, Williams SC, Volpe P, Gyorke S. Modulation of SR Ca release by luminal Ca and calsequestrin in cardiac myocytes: effects of CASQ2 mutations linked to sudden cardiac death. Biophys J 95: 2037-2048, 2008.
129. Tung CC, Lobo PA, Kimlicka L, Van Petegem F. The amino-terminal disease hotspot of ryanodine receptors forms a cytoplasmic vestibule. Nature 468: 585-588, 2010.
130. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, Shimizu W, Sumitomo N, Fish FA, Bhuiyan ZA, Willems AR, van der Veen MJ, Watanabe H, Laborderie J, Haissaguerre M, Knollmann BC, Wilde AA. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 57: 2244-2254, 2011.
131. 2+ pumps of the endoplasmic reticulum and Golgi apparatus. Cold Spring Harb Perspect Biol 3: a004184, 2011.
132. Vermassen E, Parys JB, Mauger JP. Subcellular distribution of the inositol 1,4,5-trisphosphate receptors: functional relevance and molecular determinants. Biol Cell 96: 3-17, 2004.
133. Vest JA, Wehrens XH, Reiken SR, Lehnart SE, Dobrev D, Chandra P, Danilo P, Ravens U, Rosen MR, Marks AR. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 111: 2025-2032, 2005.
134. Ward A, Chaffman MO, Sorkin Dantrolene EM. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 32: 130-168, 1986.
135. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15: 380-383, 2009.
136. Wehrens XH, Marks AR. Altered function and regulation of cardiac ryanodine receptors in cardiac disease. Trends Biochem Sci 28: 671-678, 2003.
137. Wehrens XH, Marks AR. Novel therapeutic approaches for heart failure by normalizing calcium cycling. Nat Rev Drug Discov 3: 565-573, 2004.
138. Yamazaki H, Chan J, Ikura M, Michikawa T, Mikoshiba K. Tyr-167/Trp-168 in type 1/3 inositol 1,4,5-trisphosphate receptor mediates functional coupling between ligand binding and channel opening. J Biol Chem 285: 36081-36091, 2010.
139. Yoshikawa F, Morita M, Monkawa T, Michikawa T, Furuichi T, Mikoshiba K. Mutational analysis of the ligand binding site of the inositol 1,4,5-trisphosphate receptor. J Biol Chem 271: 18277-18284, 1996.
140. Zhang Y, Chen HS, Khanna VK, De Leon S, Phillips MS, Schappert K, Britt BA, Browell AK, MacLennan DH. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 5: 46-50, 1993.
141. 2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J Biol Chem 265: 2244-2256, 1990.